menu
    • menu
    [{"orgOrder":0,"company":"Cellular Sciences","sponsor":"General University Hospital, Prague","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Cellular Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cellular Sciences \/ General University Hospital, Prague","highestDevelopmentStatusID":"10","companyTruncated":"Cellular Sciences \/ General University Hospital, Prague"},{"orgOrder":0,"company":"Cellular Sciences","sponsor":"Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cellular Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","highestDevelopmentStatusID":"9","companyTruncated":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague"},{"orgOrder":0,"company":"Cellular Sciences","sponsor":"Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cellular Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","highestDevelopmentStatusID":"9","companyTruncated":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague"},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EmphyCorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"EmphyCorp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EmphyCorp \/ Undisclosed"},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EmphyCorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"EmphyCorp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EmphyCorp \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Sodium Pyruvate

    Menu

    Sodium Pyruvate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cellular Sciences

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Cellular Sciences

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : General University Hospital, Prague

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of N115 on Coughing in IPF Patients

                            Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 14, 2023

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : General University Hospital, Prague

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EmphyCorp

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed

                            EmphyCorp

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (...

                            Details : N115 clinically and significantly reduced coughing/sneezing, fatigue, and increased SaO2 levels and synthesis of nasal nitric oxide. N115 Non-Steroidal Nasal Spray could be used as safe, effective treatment to help alleviate the symptoms associated with ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 05, 2021

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cellular Sciences

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Cellular Sciences

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.

                            Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Post-Acute COVID-19 Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 04, 2021

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cellular Sciences

                            Country arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Cellular Sciences

                            Country arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

                            Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 01, 2021

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EmphyCorp

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed

                            EmphyCorp

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EmphyCorp N115 Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide

                            Details : EmphyCorp's globally patented formula has Completed All Three Phases of Clinical Trials required by the FDA to prove safety and efficacy in treating the Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 07, 2020

                            Lead Product(s) : Sodium Pyruvate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth